Sort
30,917 grants matching “tumor microenvironment”
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy
$694,724Jennifer M Munson · Virginia Polytechnic Inst And St Univ · R01 · FY2021 · NS
Leadership Planning and Evaluation
$694,687Eric R. Fearon · University Of Michigan At Ann Arbor · P30 · FY2023 · CA
Role of inflammation, innate resistance, and immunity in carcinogenesis
$694,605Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Protein Structure, Stability, and Amyloid Formation
$694,543Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases
$694,319Elizabeth Gerstner · Massachusetts General Hospital · R01 · FY2021 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
$694,227Sharon S Evans · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis
$694,114Heide L Ford · University Of Colorado Denver · R01 · FY2020 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
$693,903Emese Zsiros · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Targeting the tumor microenvironment with engineered CD4+ T cells
$693,880Joshua R Veatch · Fred Hutchinson Cancer Center · R37 · FY2025 · CA
Targeting the tumor microenvironment with engineered CD4+ T cells
$693,880Joshua R Veatch · Fred Hutchinson Cancer Center · R37 · FY2024 · CA
A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers
$693,783Nancy Y Lee · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
$693,679William C Hahn · Dana-Farber Cancer Inst · U01 · FY2014 · CA
Core D: Data Management, Biostatistics, and Bioinformatics
$693,599David V Conti · University Of Southern California · U19 · FY2021 · CA
Cancer Genomics: Integrative and Salable Solutions in R/Bioconductor
$693,486Martin T Morgan · Roswell Park Cancer Institute Corp · U24 · FY2019 · CA
Applying pathomics to establish a biosignature for aggressive skin melanoma.
$693,456Yvonne Margaret Saenger · Columbia University Health Sciences · R01 · FY2021 · CA
Sexual dimorphism and the immuno-modulatory role of estrogen signaling in HNSCC
$693,401Sana D Karam · Washington University · R01 · FY2025 · CA
MANIPULATING THE OVARIAN CANCER TUMOR MICROENVIRONMENT TO ENHANCE NATURAL KILLER (NK) CELL KILLING
$693,000Regents Of The University Of Minnesota · · FY2020 · Defense Health Agency
Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology
$692,942Nicola J Mason · University Of Pennsylvania · U01 · FY2025 · CA
Biological determinants of colorectal cancer outcomes in Latinos of diverse ancestral origins
$692,928Stephanie L. Schmit · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
HIV integration-mediated modulation of immune regulation in HPV-associated cancers
$692,917Lisa M Frenkel · Seattle Children'S Hospital · R01 · FY2016 · CA
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
$692,707Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · CA
Multi-cellular interactions defining the human brain metastatic niche
$692,427Benjamin Izar · Columbia University Health Sciences · R01 · FY2025 · CA
Project 4: MPN-RC Clinical Consortium
$692,304John Mascarenhas · Icahn School Of Medicine At Mount Sinai · P01 · FY2020 · CA
Project 4: MPN-RC Clinical Consortium
$692,304John Mascarenhas · Icahn School Of Medicine At Mount Sinai · P01 · FY2021 · CA
Interrogating the Role of Bacterial Methyl-modifying Enzymes in Pathoadaptation and Host Epigenetic Interference in Cancer
$692,241Christopher D Johnston · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA